Translating discovery & preclinical results into predictive clinical validation in the field of metabolic and cardiovascular disorders

Physiogenex is a world leading CRO specializing in  preclinical discovery services for biopharmaceutical and nutraceutical companies.

Physiogenex has rapidly achieved global player status by virtue of its unique expertise covering complex metabolic disorders associated with diabetes, obesity, liver diseases, lipid disorders, hypertension and cardiovascular diseases.

Physiogenex pioneers the development of kinetic methods using radioactive labeled tracers and predictive animal nutritional models. We provide our partners with relevant and reliable in vivo preclinical data for successful strategic decision-making.

Physiogenex sponsors and presents scientific results at the DEUEL conference on Lipids, March 6 – 9, 2012, CA, USA.

Physiogenex is proud to partner this high-quality conference dealing with many aspects of lipid/lipoprotein metabolism.

Read more
Physiogenex to present at International Symposium on Atherosclerosis, 30 March - 1 April 2012, Australia.

Dr François Briand will present a poster on “Up-regulation of reverse cholesterol transport requires reduction of apoliprotein-E rich HDL levels in hyperlipidemic hamsters treated with CETP inhibitor torcetrapib.”

Read more
More

Unique expertise in nutritional and classical animal models
A panel of predictive models merging glucose, lipid and/or lipoprotein disorders due to nutritional imbalances, as observed in human populations

More

Leader in radioactive tracers and kinetic studies
A holistic approach to assess therapeutic efficacy on key physiological functions, and to screen potential side effects

Innovation and new products

Dr François Briand, Head of Diabetic Dyslipidemia, and Physiogenex team unveil the results of a new study that supports the potential of dipeptidyl peptidase-4 (DPP-4) inhibitors to promote Reverse Cholesterol Transport (RCT) through reduced intestinal cholesterol absorption.

Dr François Briand, Head of Diabetic Dyslipidemia, and Physiogenex team unveils the results of a new study that supports the potential of CETP inhibitors to prevent cardiovascular risk like dyslipidemia, a major characteristic of type 2 diabetic patients.

All news

Metabolic disorder diabetes

                                                                                                        Follow us